AZN up +0.62% percent Today $AZN High is at 74.65
Post# of 85
Posted On: 11/19/2014 12:38:15 PM
AZN up +0.62% percent Today $AZN High is at 74.65 and the Low 74.35 with current volume of 446,972.
Recent News posted below.
Astrazeneca Plc AZN other info.
http://investorshangout.com/AstraZeneca-PLC-AZN-50195/
AZN Astrazeneca Plc Recent Headline News
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - 56 mins ago
CLVS: 49.40 (-4.38), AZN: 75.41 (+1.43)
Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies
PR Newswire - 1 hr ago
http://www.abmrg.com/Global-Oncology-Market--...lysis.html
AZN: 75.41 (+1.43)
What The U.S. Dollar Bull Market Mean For The Global Equity Markets?
Investment Biker - at Seeking Alpha - 2 hrs 12 mins ago
SNN: 34.08 (+0.30), SPY: 205.01 (-0.54), SHPG: 208.83 (-1.17), AZN: 75.41 (+1.43), FMS: 36.43 (-0.24), GRFS: 36.76 (-0.32)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - 2 hrs 59 mins ago
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 49.40 (-4.38), AZN: 75.41 (+1.43)
Inovio-Roche End Deal for Development of Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:26PM CST
Inovio Pharmaceuticals, Inc. (INO) announced the termination of its agreement with Roche for the co-development of Inovio's prostate cancer candidate, INO-5150.
INO: 9.54 (-0.32), AZN: 75.41 (+1.43), BMY: 58.60 (-0.10)
AstraZeneca details organic growth plan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:52AM CST
AZN: 75.41 (+1.43)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.59 (-0.11), PFE: 30.32 (-0.27), AZN: 75.41 (+1.43), LLY: 67.32 (-0.46), GSK: 46.34 (+0.06), NVS: 95.80 (+0.22)
Wall Street Breakfast: Abe Delays Sales Tax Hike
Wall Street Breakfast - Seeking Alpha - Tue Nov 18, 5:31AM CST
Economy Japanese Prime Minister Shinzo Abe says he will delay a sales tax rise and call a snap election, a day after data showed the economy had contracted for two successive quarters, dragged down by a rise in the consumption tax in April....
RAI: 65.51 (+0.21), GOMO: 6.09 (-0.11), FB: 74.11 (-0.23), PFE: 30.32 (-0.27), SNE: 20.84 (-0.42), INTC: 34.50 (-0.21), GOOG: 534.27 (-0.76), T: 35.37 (-0.35), SPY: 205.01 (-0.54), QQQ: 103.25 (-0.43), TRP: 50.71 (+1.14), S: 4.74 (-0.02), AZN: 75.41 (+1.43), EDGW: 8.07 (+0.10), GOOGL: 544.01 (-0.50), ACCO: 8.98 (+0.09)
AstraZeneca forecasts $45B in annual sales by 2023
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:35AM CST
AZN: 75.41 (+1.43)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.33 (-0.50), GILD: 101.97 (-1.74), GERN: 3.19 (+0.02), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43), PFE: 30.32 (-0.27), INCY: 71.81 (+2.17), BMY: 58.60 (-0.10), CTIC: 2.23 (-0.05), NVS: 95.80 (+0.22)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.83 (-1.17), PFE: 30.32 (-0.27), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43), ABBV: 65.57 (-0.48)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.32 (-0.27), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 141.22 (-0.72), ACT: 268.60 (-1.00), F: 15.43 (-0.07), FB: 74.11 (-0.23), PFE: 30.32 (-0.27), AGN: 213.79 (+0.42), YHOO: 51.05 (-0.70), PBR: 9.48 (+0.06), DFS: 64.33 (-0.65), DTSI: 31.62 (-1.07), SPY: 205.01 (-0.54), LNKD: 220.48 (-0.59), QQQ: 103.24 (-0.44), AME: 50.91 (+0.20), MRK: 59.49 (-0.40), AOL: 45.06 (-0.64), AZN: 75.41 (+1.43), GM: 32.26 (-0.01), CVEO: 10.16 (-0.08), DD: 70.94 (-0.22)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 75.41 (+1.43), MRK: 59.49 (-0.40), PFE: 30.32 (-0.27)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 75.41 (+1.43), LLY: 67.32 (-0.46), ABBV: 65.57 (-0.48), GSK: 46.34 (+0.06), SNY: 48.21 (-0.15), NVS: 95.80 (+0.22)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.32 (-0.27), AZN: 75.41 (+1.43), ABBV: 65.57 (-0.48)
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting
Business Wire - Sun Nov 16, 8:00AM CST
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. The data was presented as a late-breaking presentation at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA.
AZN: 75.41 (+1.43)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
ITMN: 73.89 (-0.02), IPF: 21.74 (-0.15), AZN: 75.41 (+1.43), FGEN: 23.76 (+0.17)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.78 (-1.78), ISIS: 50.85 (+1.14), AZN: 75.41 (+1.43), SNY: 48.21 (-0.15)
Cramer sees Dow Chemical in "smart, aggressive buyback"
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:38AM CST
DPS: 70.73 (-0.17), JACK: 75.66 (+4.16), FLEX: 11.01 (-0.07), VIA: 73.24 (-0.75), AZN: 75.41 (+1.43), KMB: 113.50 (-0.10), DIS: 89.40 (-0.88), M: 61.86 (+0.41), DOW: 51.59 (-0.48)
Recent News posted below.
Astrazeneca Plc AZN other info.
http://investorshangout.com/AstraZeneca-PLC-AZN-50195/
AZN Astrazeneca Plc Recent Headline News
CO-1686 Data Confirmed Efficacy, Take Advantage Of Weakness In Clovis Oncology Shares Ahead Of Rucaparib Outcomes Data
Dr. Paul Nunzio DeSantis, Pharm.D - at Seeking Alpha - 56 mins ago
CLVS: 49.40 (-4.38), AZN: 75.41 (+1.43)
Global Oncology Market to hit $109 billion - Spotlight on Drug Life Cycle Management, M&A and Pipeline Strategies
PR Newswire - 1 hr ago
http://www.abmrg.com/Global-Oncology-Market--...lysis.html
AZN: 75.41 (+1.43)
What The U.S. Dollar Bull Market Mean For The Global Equity Markets?
Investment Biker - at Seeking Alpha - 2 hrs 12 mins ago
SNN: 34.08 (+0.30), SPY: 205.01 (-0.54), SHPG: 208.83 (-1.17), AZN: 75.41 (+1.43), FMS: 36.43 (-0.24), GRFS: 36.76 (-0.32)
Clovis Lung Cancer Update Swings Momentum to Rival, Slightly
at The Street - 2 hrs 59 mins ago
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
CLVS: 49.40 (-4.38), AZN: 75.41 (+1.43)
Inovio-Roche End Deal for Development of Cancer Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:26PM CST
Inovio Pharmaceuticals, Inc. (INO) announced the termination of its agreement with Roche for the co-development of Inovio's prostate cancer candidate, INO-5150.
INO: 9.54 (-0.32), AZN: 75.41 (+1.43), BMY: 58.60 (-0.10)
AstraZeneca details organic growth plan
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 9:52AM CST
AZN: 75.41 (+1.43)
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - Tue Nov 18, 9:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.59 (-0.11), PFE: 30.32 (-0.27), AZN: 75.41 (+1.43), LLY: 67.32 (-0.46), GSK: 46.34 (+0.06), NVS: 95.80 (+0.22)
Wall Street Breakfast: Abe Delays Sales Tax Hike
Wall Street Breakfast - Seeking Alpha - Tue Nov 18, 5:31AM CST
Economy Japanese Prime Minister Shinzo Abe says he will delay a sales tax rise and call a snap election, a day after data showed the economy had contracted for two successive quarters, dragged down by a rise in the consumption tax in April....
RAI: 65.51 (+0.21), GOMO: 6.09 (-0.11), FB: 74.11 (-0.23), PFE: 30.32 (-0.27), SNE: 20.84 (-0.42), INTC: 34.50 (-0.21), GOOG: 534.27 (-0.76), T: 35.37 (-0.35), SPY: 205.01 (-0.54), QQQ: 103.25 (-0.43), TRP: 50.71 (+1.14), S: 4.74 (-0.02), AZN: 75.41 (+1.43), EDGW: 8.07 (+0.10), GOOGL: 544.01 (-0.50), ACCO: 8.98 (+0.09)
AstraZeneca forecasts $45B in annual sales by 2023
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:35AM CST
AZN: 75.41 (+1.43)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.33 (-0.50), GILD: 101.97 (-1.74), GERN: 3.19 (+0.02), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43), PFE: 30.32 (-0.27), INCY: 71.81 (+2.17), BMY: 58.60 (-0.10), CTIC: 2.23 (-0.05), NVS: 95.80 (+0.22)
Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.83 (-1.17), PFE: 30.32 (-0.27), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43), ABBV: 65.57 (-0.48)
Pfizer Strikes Immuno-oncology Pact with Merck After Abandoning AstraZeneca
at The Street - Mon Nov 17, 9:04AM CST
The transaction includes an upfront payment of $850 million to the German company, followed by up to $2 billion in milestone rewards.
PFE: 30.32 (-0.27), MRK: 59.49 (-0.40), AZN: 75.41 (+1.43)
Wall Street Breakfast: Nikkei Dives As Japan Slips Into Recession
Wall Street Breakfast - Seeking Alpha - Mon Nov 17, 5:30AM CST
Outstanding Performance Article Rewards We're excited to announce our latest two Outstanding Performance award winners. Each author receives $2,500. Read more about our Outstanding Performance award winners here . Winner #1: Top long idea...
VRX: 141.22 (-0.72), ACT: 268.60 (-1.00), F: 15.43 (-0.07), FB: 74.11 (-0.23), PFE: 30.32 (-0.27), AGN: 213.79 (+0.42), YHOO: 51.05 (-0.70), PBR: 9.48 (+0.06), DFS: 64.33 (-0.65), DTSI: 31.62 (-1.07), SPY: 205.01 (-0.54), LNKD: 220.48 (-0.59), QQQ: 103.24 (-0.44), AME: 50.91 (+0.20), MRK: 59.49 (-0.40), AOL: 45.06 (-0.64), AZN: 75.41 (+1.43), GM: 32.26 (-0.01), CVEO: 10.16 (-0.08), DD: 70.94 (-0.22)
Pfizer cuts profit outlook after Merck deal
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:06AM CST
AZN: 75.41 (+1.43), MRK: 59.49 (-0.40), PFE: 30.32 (-0.27)
7 Biggest Health Problems Americans Face
Keith Speights, The Motley Fool - Motley Fool - Sun Nov 16, 12:00PM CST
Americans include two health-related issues among the 10 most important problems facing the U.S., according to a recent Gallup survey . Healthcare in general ranked fourth on the list, with Ebola coming in at no. 8. But is Ebola really among the...
AZN: 75.41 (+1.43), LLY: 67.32 (-0.46), ABBV: 65.57 (-0.48), GSK: 46.34 (+0.06), SNY: 48.21 (-0.15), NVS: 95.80 (+0.22)
AbbVie Inc. vs. Pfizer Inc.: Which Is the Better Dividend Stock?
George Budwell, The Motley Fool - Motley Fool - Sun Nov 16, 9:20AM CST
Dividend stocks are powerful long-term investing vehicles that should be an integral part of a well balanced portfolio. Picking good dividend stocks, though, is another story altogether. High dividend yields may be an artificial by-product of a...
PFE: 30.32 (-0.27), AZN: 75.41 (+1.43), ABBV: 65.57 (-0.48)
AstraZeneca Presents Data from Phase III Studies of Lesinurad in Combination with Allopurinol in Gout Patients at American College of Rheumatology 2014 Annual Meeting
Business Wire - Sun Nov 16, 8:00AM CST
AstraZeneca (NYSE: AZN) today presented top-line results of two pivotal Phase III trials investigating the potential of lesinurad, a selective uric acid re-absorption inhibitor (SURI), when used in combination with xanthine oxidase (XO) inhibitor allopurinol. The results show that approximately twice as many patients met the primary endpoint with a statistically significant higher proportion of patients reaching the target sUA goal of <6.0 mg/dL at month 6, compared to those treated with allopurinol alone. The data was presented as a late-breaking presentation at the American College of Rheumatology (ACR) 2014 Annual Meeting in Boston, Massachusetts. Lesinurad is an investigational agent that inhibits the uric acid transporter URAT1 in the kidney, increasing uric acid excretion and thereby lowering sUA.
AZN: 75.41 (+1.43)
FibroGen Looks Healthy Heading Into IPO
Don Dion - at Seeking Alpha - Fri Nov 14, 3:30PM CST
ITMN: 73.89 (-0.02), IPF: 21.74 (-0.15), AZN: 75.41 (+1.43), FGEN: 23.76 (+0.17)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 303.78 (-1.78), ISIS: 50.85 (+1.14), AZN: 75.41 (+1.43), SNY: 48.21 (-0.15)
Cramer sees Dow Chemical in "smart, aggressive buyback"
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:38AM CST
DPS: 70.73 (-0.17), JACK: 75.66 (+4.16), FLEX: 11.01 (-0.07), VIA: 73.24 (-0.75), AZN: 75.41 (+1.43), KMB: 113.50 (-0.10), DIS: 89.40 (-0.88), M: 61.86 (+0.41), DOW: 51.59 (-0.48)
(0)
(0)AstraZeneca PLC (AZN) Stock Research Links
Scroll down for more posts ▼